Company: AEMD
Filing Date: 2025-02-12
Form Type: 10-Q
Source: 0001683168-25-000960
Chunk: 82

Company: AETHLON MEDICAL INC
Filing Date: 2025-02-12
Form: 10-Q
Item: Item 2
Chunk 82
---
, with no comparable purchases during the current period. Additionally, there was a $63,686
decrease in insurance expenses associated with a reduced headcount and a $22,708 reduction in various other operating expenses. These
reductions were partially offset by a $176,877 increase in expenses related to our ongoing oncology clinical trials in Australia and India.

 22 

Net Loss

As a result of the changes in expenses noted above,
our comprehensive loss decreased to $1,767,840 in the three months ended December 31, 2024 from $3,458,170 in the three months ended December
31, 2023.

Basic and diluted loss attributable to common
stockholders was ($0.13) for the three months ended December 31, 2024, compared to ($1.37) for the three-month period ended December 31,
2023.

NINE MONTHS ENDED DECEMBER 31, 2024 COMPARED TO THE NINE MONTHS ENDED
DECEMBER 31, 2023

Operating Expenses

Consolidated operating expenses for the nine months
ended December 31, 2024 decreased by $2,813,192 to $7,337,402 compared to $10,150,594 for the nine months ended December 31, 2023. This
decrease of $2,813,192, or 27.7%, in the 2024 period was due to decreases in our professional fees of $1,214,340, payroll and related
expenses of $985,783 and general and administrative expenses of $613,069.

The $1,214,340 decrease in professional fees was
mainly due to a $654,232 reduction in contract labor costs related to completed projects with a contract manufacturing organization, as
well as with outside research and development and regulatory and quality management consultants. Additional decreases included $525,035
in legal fees which includes $503,769 decrease following a transition to a new legal firm, $13,952 decrease in fees related to stock split
with no comparable expense in current period, and a $7,315 decrease in legal fees related to patent matters as well as a $62,500 reduction
in recruiting fees. These decreases were offset by a $33,428 increase in investor relation fees.

The $985,783 decrease in payroll and related expenses
was primarily driven by a $737,458 reduction in stock-based compensation which includes $393